Agile Therapeutics (AGRX) Stock Price, News & Analysis

Company Overview

Agile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.

Key Stats

• Today's Range: $1.51 to $1.52
• 50-Day Range: $1.43 to $1.51
• 52-Week Range: $0.20 to $2.63
• Volume: 120,938 shs
• Average Volume: 352,864 shs
• Market Capitalization: $10.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AGRX Stock Analysis - Frequently Asked Questions

How were Agile Therapeutics' earnings last quarter?

Agile Therapeutics, Inc. (NASDAQ:AGRX) announced its quarterly earnings results on Tuesday, November, 2nd. The specialty pharmaceutical company reported ($7.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($7.60) by $0.40. The specialty pharmaceutical company had revenue of $1.29 million for the quarter, compared to the consensus estimate of $1.49 million.
Read the conference call transcript.

When did Agile Therapeutics' stock split?

Agile Therapeutics shares reverse split before market open on Wednesday, April 27th 2022.The 1-40 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Agile Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Agile Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), CrowdStrike (CRWD) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 11/02/2021
• Today: 9/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AGRX
• CIK: 1261249
• Web: www.agiletherapeutics.com
• Phone: (609) 683-1880
• Fax: N/A
• Employees: 30
• Year Founded: 1997

Profitability

• EPS (Trailing Twelve Months): ($3.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.47 million
• Net Margins: -36.24%
• Pretax Margin: -36.24%
• Return on Equity: N/A
• Return on Assets: -147.37%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.56
• Quick Ratio: 0.38

Sales & Book Value

• Annual Sales: $19.98 million
• Price / Sales: 0.52
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($5.51) per share
• Price / Book: -0.27

Miscellaneous

• Outstanding Shares: 6,856,000
• Free Float: 6,822,000
• Market Cap: $10.35 million
• Optionable: Not Optionable
• Beta: 1.58